New pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme- and cell-based investigations

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 1, 2009, Pages 235-247

  Mai, Antonello ^a   Valente, Sergio ^a   Nebbioso, Angela ^b   Simeoni, Silvia ^a   Ragno, Rino ^a   Massa, Silvio ^c   Brosch, Gerald ^d   De Bellis, Floriana ^b,e   Manzo, Fabio ^b   Altucci, Lucia ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e IGBCM   (France)

Author keywords

Apoptosis; Aroyl pyrrolyl hydroxyamides; Chromatin remodelling; Cytodifferentiation; Histone deacetylase

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; VORINOSTAT;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL STRAIN U937; CHEMICAL MODIFICATION; DRUG MECHANISM; ENZYME BINDING; EVOLUTIONARY HOMOLOGY; HUMAN; HUMAN CELL; HYDROPHOBICITY; STRUCTURAL HOMOLOGY;

APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; U937 CELLS;

MURINAE; ZEA MAYS;

EID: 55949088703     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.09.002     Document Type: Article

References (62)

1. Altucci L., Rossin A., Raffelsberger W., Reitmair A., Chomienne C., and Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 7 (2001) 680-686
2. Altucci L., Clarke N., Nebbioso A., Scognamiglio A., and Gronemeyer H. Acute myeloid leukemia: therapeutic impact of epigenetic drugs. Int J Biochem Cell Biol 37 (2005) 1752-1762
3. Artico M., Corelli F., Massa S., and Stefancich G. Nonsteroidal antiinflammatory agents. 1. A novel synthesis of 1-methyl-5-p-tolylpyrrole-2-acetic acid (Tolmetin). J Heterocycl Chem 19 (1982) 1493-1495
4. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5 (2006) 769-784
5. Brosch G., Georgieva E.I., Lopez-Rodas G., Lindner H., and Loidl P. Specificity of Zea mays histone deacetylase is regulated by phosphorylation. J Biol Chem 267 (1992) 20561-20564
6. Brosch G., Goralik-Schramel M., and Loidl P. Purification of histone deacetylase HD1-A of germinating maize embryos. FEBS Lett 393 (1996) 287-291
7. Brosch G., Lusser A., Goralik-Schramel M., and Loidl P. Purification and characterization of a high molecular weight histone deacetylase complex (HD2) of maize embryos. Biochemistry (Mosc) 35 (1996) 15907-15914
8. Budillon A., Di Gennaro E., Bruzzese F., Rocco M., Manzo G., and Caraglia M. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. Recent Patients Anticancer Drug Discov 2 (2007) 119-134
9. Butler K.V., and Kozikowski A.P. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des 14 (2008) 505-528
10. Carson JR, Codd EE, Pitis PM. Preparation of (aroyl)pyrrolyl heteroaryl methanones and methanols as central nervous system agents. PCT/WO/2003/057219; 2003a [December 10, 2002].
11. Carson JR, Codd EE, Pitits PM. Preparation of (aroyl)pyrrolyl heteroaryl methanones and methanols as central nervous system agents. PCT/WO/2003/057147; 2003b [December 23, 2002].
12. Carson J.R., and Davis N.M. Acid-mediated rearrangement of acylpyrroles. J Org Chem 46 (1981) 839-843
13. Carson JR, Pitis PM. Preparation of aroyl aminoacyl pyrroles as CNS agents. PCT/WO/2002002521; 2002 [June 29, 2001].
14. Carson JR, Pitis PM, Rogers KE. Preparation of aminoacyl(aroyl)pyrroles for treatment of neuropathic pain. PCT/WO/2000048584; 2000 [February 17, 2000].
15. Case D.A., Cheatham III T.E., Darden T., Gohlke H., Luo R., Merz Jr. K.M., et al. The Amber biomolecular simulation programs. J Comput Chem 26 (2005) 1668-1688
16. Cheung W.L., Briggs S.D., and Allis C.D. Acetylation and chromosomal functions. Curr Opin Cell Biol 12 (2000) 326-333
17. Condorelli F., Gnemmi I., Vallario A., Genazzani A.A., and Canonico P.L. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 153 (2008) 657-668
18. Corelli F., Massa S., Stefancich G., Mai A., Artico M., Panico S., et al. Antibacterial and antifungal compounds. VIII. Synthesis and antifungal activity of pyrrol derivatives similar to trichostatin A. Farmacology [Sci] 42 (1987) 893-903
19. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
20. Glozak M.A., Sengupta N., Zhang X., and Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363 (2005) 15-23
21. Goodsell D.S., Morris G.M., and Olson A.J. Automated docking of flexible ligands: applications of AutoDock. J Mol Recogn 9 (1996) 1-5
22. Grant S., Easley C., and Kirkpatrick P. Vorinostat. Nat Rev Drug Discov 6 (2007) 21-22
23. Grozinger C.M., and Schreiber S.L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 9 (2002) 3-16
24. Itoh Y., Suzuki T., and Miyata N. Isoform-selective histone deacetylase inhibitors. Curr Pharm Des 14 (2008) 529-544
25. Jain A.N. Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des 21 (2007) 281-306
26. Jones P., and Steinkuhler C. From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents. Curr Pharm Des FIELD (Full Journal Title: Current Pharmaceutical Design) 14 (2008) 545-561
27. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409 (2008) 581-589
28. Kolle D., Brosch G., Lechner T., Lusser A., and Loidl P. Biochemical methods for analysis of histone deacetylases. Methods 15 (1998) 323-331
29. Kolle D., Brosch G., Lechner T., Pipal A., Helliger W., Taplick J., et al. Different types of maize histone deacetylases are distinguished by a highly complex substrate and site specificity. Biochemistry (Mosc) 38 (1999) 6769-6773
30. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 9 (1999) 40-48
31. Krause S., Willighagen E., and Steinbeck C. JChemPaint-using the collaborative forces of the internet to develop a free editor for 2D chemical structures. Molecules 5 (2000) 93-98
32. Lechner T., Lusser A., Brosch G., Eberharter A., Goralik-Schramel M., and Loidl P. A comparative study of histone deacetylases of plant, fungal and vertebrate cells. Biochim Biophys Acta 1296 (1996) 181-188
33. Lechner T., Lusser A., Pipal A., Brosch G., Loidl A., Goralik-Schramel M., et al. RPD3-type histone deacetylases in maize embryos. Biochemistry (Mosc) 39 (2000) 1683-1692
34. Lee SJ, Seko T, Frierson MR, Sircar JC, Cao CX. Preparation of 2-(pyrrol-2-yl)acetic acids as 5alpha-reductase inhibitors. PCT/WO/9610013; 1996 [September 27, 1995].
35. Lusser A., Brosch G., Loidl A., Haas H., and Loidl P. Identification of maize histone deacetylase HD2 as an acidic nucleolar phosphoprotein. Science 277 (1997) 88-91
36. Mai A., Massa S., Cerbara I., Valente S., Ragno R., Bottoni P., et al. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity. J Med Chem 47 (2004) 1098-1109
37. Mai A., Massa S., Pezzi R., Rotili D., Loidl P., and Brosch G. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J Med Chem 46 (2003) 4826-4829
38. Mai A., Massa S., Ragno R., Esposito M., Sbardella G., Nocca G., et al. Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. J Med Chem 45 (2002) 1778-1784
39. Mai A., Massa S., Valente S., Simeoni S., Ragno R., Bottoni P., et al. Aroyl-pyrrolyl hydroxyamides: influence of pyrrole C4-phenylacetyl substitution on histone deacetylase inhibition. ChemMedChem 1 (2006) 225-237
40. Mai A., Valente S., Rotili D., Massa S., Botta G., Brosch G., et al. Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. Int J Biochem Cell Biol 39 (2007) 1510-1522
41. Manzo F., Nebbioso A., Miceli M., Conte M., De Bellis F., Carafa V., et al. TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule. Int J Biochem Cell Biol (2008) 012 10.1016/j.biocel.2007.12.012
42. Marks P.A., and Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25 (2007) 84-90
43. Marumo S, Aoyagi K, Hamamura H, Nakayama A, Sano H. Preparation of 2-acylpyrrole derbenzoyl, 2-furoyl, and 2-thenoylivatives as agricultural or horticultural fungicides. PCT/WO/2002085852; 2002 [April 17, 2002].
44. Massa S., Mai A., Sbardella G., Esposito M., Ragno R., Loidl P., et al. 3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. J Med Chem 44 (2001) 2069-2072
45. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 (2006) 38-51
46. Morris G.M., Goodsell D.S., Huey R., and Olson A.J. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des 10 (1996) 293-304
47. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., et al. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19 (1998) 1639-1662
48. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11 (2005) 77-84
49. Nielsen T.K., Hildmann C., Dickmanns A., Schwienhorst A., and Ficner R. Crystal structure of a bacterial class 2 histone deacetylase homologue. J Mol Biol 354 (2005) 107-120
50. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., et al. UCSF chimera-a visualization system for exploratory research and analysis. J Comput Chem 25 (2004) 1605-1612
51. Ragno R., Mai A., Massa S., Cerbara I., Valente S., Bottoni P., et al. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors 3. Discovery of novel lead compounds through structure-based drug design and docking studies. J Med Chem 47 (2004) 1351-1359
52. Ragno R., Simeoni S., Rotili D., Caroli A., Botta G., Brosch G., et al. Class II-selective histone deacetylase inhibitors. Alignment-independent GRIND 3-D QSAR, homology and docking studies. Eur J Med Chem FIELD (Full Journal Title: European Journal of Medicinal Chemistry) 43 (2008) 621-632
53. Ragno R., Simeoni S., Valente S., Massa S., and Mai A. 3-D QSAR studies on histone deacetylase inhibitors. A GOLPE/GRID approach on different series of compounds. J Chem Inform Model 46 (2006) 1420-1430
54. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95 (1998) 3003-3007
55. Somoza J.R., Skene R.J., Katz B.A., Mol C., Ho J.D., Jennings A.J., et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12 (2004) 1325-1334
56. Steinbeck C., Han Y., Kuhn S., Horlacher O., Luttmann E., and Willighagen E. The chemistry development kit (CDK): an open-source Java library for Chemo- and bioinformatics. J Chem Inform Comput Sci 43 (2003) 493-500
57. Steinbeck C., Hoppe C., Kuhn S., Floris M., Guha R., and Willighagen E.L. Recent developments of the chemistry development kit (CDK)-an open-source java library for chemo- and bioinformatics. Curr Pharm Des 12 (2006) 2111-2120
58. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
59. Vigushin D.M., and Coombes R.C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13 (2002) 1-13
60. Wolffe A.P., and Guschin D. Review: chromatin structural features and targets that regulate transcription. J Struct Biol 129 (2000) 102-122
61. Wu J., and Grunstein M. 25 years after the nucleosome model: chromatin modifications. Trends Biochem Sci 25 (2000) 619-623
62. Yoshida M., Kijima M., Akita M., and Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265 (1990) 17174-17179